Carcinoma of supraglottis

Summary

Carcinoma of supraglottis (MONDO:0004357) is a cancer and 2 clinical trials. A subtype of supraglottis cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinoma of supraglottis
Mondo ID	MONDO:0004357
DOID	DOID:7763
NCIT	C5973
SNOMED CT	372105009
UMLS	C1299240
MedGen	266243
GARD	0009478
Anatomy (UBERON)	UBERON:0036263
Is cancer (heuristic)	yes

Also known as: cancer of supraglottis · cancer of the supraglottis · carcinoma of supraglottic part of larynx · carcinoma of supraglottis · carcinoma of the supraglottis · supraglottic cancer · supraglottic carcinoma · supraglottic part of larynx carcinoma · supraglottic throat cancer · supraglottis carcinoma

Disease family

This is a subtype of supraglottis cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › larynx cancer › supraglottis cancer › carcinoma of supraglottis

Subtypes (2): supraglottis squamous cell carcinoma, epiglottis cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03358602	Not specified	NOT_YET_RECRUITING	Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer
NCT04908696	Not specified	RECRUITING	Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)